Whole-body magnetic resonance imaging

DIAGNOSTIC_TEST2 trials

Sponsors

Turku University Hospital, Nicole Baca

Conditions

High Risk Prostate CancerNeurofibromatosis Type 1

Unknown Phase

Novel Imaging in Staging of Primary Prostate Cancer

CompletedNCT03537391

Turku University HospitalHigh Risk Prostate Cancer

Start: 2018-03-01End: 2022-05-02Updated: 2022-05-04

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

RecruitingNCT04763109

Nicole BacaNeurofibromatosis Type 1

Start: 2022-07-08End: 2029-05-01Target: 15Updated: 2026-05-07

Related Papers

Prospective comparison of <sup>18</sup>F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer.

2025-03-313 citations

Characterization of pre-malignant lesions in patients with pediatric neurofibromatosis type 1 using a novel whole-body magnetic resonance imaging technique.

Journal of Clinical Oncology2023-06-011 citations

Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer

Nuclear Medicine Communications2022-01-2510 citations

Prospective comparison of <sup>18</sup>F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer.

2021-03-1333 citations

A Prospective Comparison of <sup>18</sup>F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).

2020-07-1371 citations

MP62-18 PRIMARY METASTASIS STAGING USING <sup>18</sup> F-PSMA-1007 PET-CT IN HIGH-RISK PROSTATE CANCER

The Journal of Urology2020-04-01